Androxal (enclomiphine)- a new form of Clomid on the market!

It seems like every few weeks I hear about a new drug, or at least a new take on an old favorite. Earlier today I spoke with a doctor of biochemistry who enlightened me about Androxal, a Selective Estrogen Receptor Antagonist (SERA) that is poised to take over the position Clomid/Nolvadex once held for PCT. It's been on my radar for a few years now, but it's entering the final stages of clinical development after being stalled, and I'm pretty sure it isn't too far from hitting the research chem market and becoming widely available.

It's being studied for the treatment of male hypogonadism by Respros Theraputics

Androxal is a drug containing Enclomiphene, the trans-stereoisomer of Clomiphene Citrate (Clomid). It promotes gonadotropin-dependent testosterone secretion by the testes, similar to Clomid, although significantly stronger on a Mg/Mg basis. I'm also suspecting that since it's an estrogen antagonist and not a mixed agonist/antagonist (like Clomid is), it won't cause the emotional side effects common with Clomid. Let's take a look at the science, and see what we can expect, in terms of testosterone, LH, and FSH elevation from this product:

In a six month, double-blind study two doses of oral Androxal (12.5mg and 25mg) were tested.

At the end of the study 72.7% and 79.2%, respectively, of men in the 12.5mg and 25mg treatment arms had total testosterone in the normal physiological range. At month three, the mean improvement in testosterone levels was 184.3 and 259.2 ng/dl for both the 12.5mg and 25mg dose of androxal (which is significantly higher than either Clomid or Nolvadex will likely produce). After three months of treatment with Androxal, LH levels increased to normal values of 5.8 and 8.1 (in the 12.5mg and 25mg groups, respectively). FSH showed a similar increase as well.

It also exhibited a favorable effect on fasting plasma glucose, probably due to the bidirectional relationship between low serum testosterone and obesity/metabolic syndrome (syndrome X) in men.

Obviously this is great news for people coming off a cycle, as it's a more effective product than either Nolvadex or Clomid for elevating testosterone levels via estrogen antagonism. It may not have some of the beneficial effects that we expect from those other compounds, though, such as increasing bone mineral density or favorable effects on lipids, but then again, that's not what we're really attempting to do while on PCT.

If available, this would become my #1 choice for PCT, especially if it could be used in conjunction with Orvidrel. It's going to be a race now, to see which research chem company is first to bring it to the market, and what the feedback is from people who try it.

Subscribe to RxMuscle on Youtube


300x250 Design


300x250 Design